WEX PHARMACEUTICALS INC. ANNOUNCES ABSTRACT AND POSTER PRESENTATION ON HALNEURON® AT PAIN IN EUROPE XIII: THE 13TH CONGRESS OF THE EUROPEAN PAIN FEDERATION EFIC®

Vancouver, BC (September 12, 2023) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a clinical-stage biotechnology company developing Halneuron^® (Tetrodotoxin or TTX) for pain, is pleased to announce that a poster presentation on the Company’s lead drug candidate Halneuron® was accepted for presentation at the 13^th Congress of the European Pain Federation (EFIC®) being held at Budapest, Hungary from September 20^th to 22^nd, 2023.